Rainer Niedtner

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
445 Background: Optimizing outcomes in RCC or GIST patients (pts) receiving TKI (e.g. sunitinib ([U]) involves therapy management as a key component. Reduction/elimination of adverse events (AEs) by(More)
  • 1